BioTech IP Review

Soluble TCRs and Methods of Use Thereof

  • Applicant / Assignee: BioNTech SE
  • Patent Application (PCT): PCT/IB2025/054084
  • Publication Number: WO/2025/219955
  • Filing Date: April 17, 2025
  • Publication Date: October 23, 2025
  • Title: Soluble TCRs and Methods of Use Thereof

What It Covers

This patent application describes soluble T-cell receptors (TCRs) and related compositions and methods — a technology central to novel immunotherapy approaches that can be used therapeutically or diagnostically in cancer and infectious disease settings:

  • Soluble T-cell receptors (TCRs): These are engineered versions of natural TCR proteins that are not cell-bound but instead exist as soluble proteins. They retain the ability to specifically recognize peptide antigens presented by major histocompatibility complex (MHC) molecules on target cells.
  • Therapeutic use: The patent claims ways to use these soluble TCRs — for example, as targeting moieties to engage tumor antigens or infected cells, potentially directing immune effector mechanisms or delivering payloads to specific cells.
  • Compositions and methods: It also covers formulations and methods of administering these soluble TCRs, alone or in combination with other therapeutic agents, to treat diseases that involve specific antigen expression (e.g., cancer).

Why It’s Important

1. Strategic Expansion Beyond mRNA Vaccines

BioNTech’s global profile was built on its mRNA vaccines (notably Comirnaty), but the company is actively broadening into immuno-oncology and cell-based therapies. Soluble TCRs represent a next-generation biologic modality for targeting intracellular antigens — an advantage over traditional antibody therapies.

2. High Clinical Relevance

Soluble TCRs can recognize peptide/MHC complexes derived from intracellular proteins — including neoantigens unique to tumor cells — enabling very precise targeting. This has major implications for cancer immunotherapy, where such precision could translate into higher therapeutic benefit and fewer off-target effects.

3. Broad IP Protection

A patent claiming both the soluble TCR proteins and their methods of use provides BioNTech with a durable intellectual property position as it develops proprietary immunotherapies, including potential CAR-T enhancements, bispecifics, or payload-conjugated targeting agents.

4. Commercial Potential

Therapies based on soluble TCRs could tap into multi-billion-dollar oncology and chronic disease markets, particularly if coupled with BioNTech’s mRNA manufacturing and delivery expertise. This fits with BioNTech’s broader strategy of leveraging its platform across vaccines, cancer immunotherapies, and personalized medicine.

Summary

PCT/IB2025/054084 — “Soluble TCRs and Methods of Use Thereof,” filed April 17, 2025 and published as WO/2025/219955 on October 23, 2025, protects engineered soluble T-cell receptors and their therapeutic implementations. This technology positions BioNTech to expand into precision immunotherapies — offering a platform that could be pivotal in treating cancers and other diseases where specific antigen targeting is critical.

Leave a comment